BioCentury
ARTICLE | Clinical News

GEN-003: Completed Phase II enrollment

January 19, 2015 8:00 AM UTC

Genocea completed enrollment of >300 patients in a double-blind, placebo-controlled, U.S. Phase II trial evaluating 30 and 60 µg intramuscular GEN-003 containing 25, 50 or 75 µg Matrix M given 3 times...